|
|
 |
|
Viewing report
|
|
|
|
Interacting with KOLs: fulfilling current unmet needs
FirstWord Publishing, Dec 2011, Pages: 41
The symbiotic relationship between key opinion leaders (KOLs) and the pharmaceutical industry is dynamic and ever-changing. But while the industry knows what it wants from KOLs, what do KOLs need from the industry?
In a fascinating new premium series, FirstWord digs into the mindset of leading KOLs from around the world to offer the industry their views on critical issues. Focusing on different KOL groups, the series will deliver insights that will not only help the industry understand KOL needs, but strengthen the relationship and use their work even more strategically to maximize the value of KOL expertise and influence.
In Interacting with Oncology KOLs: Fulfilling Unmet Needs, FirstWord examines the impact of transparency on KOLs and their strong desire for greater involvement in drug development, trial design and post-trial follow up. The report, based on interviews with 15 KOLs from across Europe, the US and Canada, uncovers oncology KOLs’ views on the industry’s digital media usage, level of disease knowledge amongst pharma personnel, CME spending and the high staff turnover rate within the industry. Offering the KOL perspective on what works, what doesn’t and what they want to see going forward, the report delivers exceptional and decisive insight into the KOL mind.
Key Report Features
- Opinions from 15 KOLs based at oncology centers in North America and Europe
- Insight into how KOLs view transparency and how it will impact KOL-industry relationships going forward
- How KOLs expertise can be utilized in trial design and strategies
- Insight into how to maximize benefits from the KOL-industry relationship in areas such as CME
- Perspectives from KOLs on future partnerships and constructive change
Key Benefits
- Expert insight from KOLs that will provide insight for strategizing and ensuring maximum impact from clinician partnerships
- Insight on the cornerstones of the KOL-industry relationship and how they can be influenced
- Specific examples showing how KOL engagement can be improved
Key Questions Asked
- What are the key issues KOLs raise regarding their relationship with industry?
- How is transparency being received and how is it affecting KOL work?
- What changes do KOLs want to see in regards to issues like digital media and the requirements of oncologists?
- How KOLs see their role in trial design and post-trial feedback?
Expert Views Include:
- Professor and Director, Myeloma Research, John Theurer Cancer Center at HUMC, New Jersey, US
- Professor and Oncologist at Cancer Medicine Department, Istituto Nazionale Tumori, Italy
- Professor of Oncology and Head of the Department of Medical Oncology at the University Hospital Antwerp, Belgium
- Senior Vice President of Clinical Affairs and National Director for Medical Oncology, Cancer Treatment Centers of America , US
- Associate Professor of Medicine, Division of Cancer Medicine and Blood Diseases at University of Southern California, US
- Haemotologist and Oncologist at University of Copenhagen, Denmark
- Medical Director of the Tulane Cancer Center at Tulane University, New Orleans, US
- Oncologist at Sunnybrook Health Sciences Centre and Professor of Surgery at the University of Toronto, Canada
- Professor and oncologist at University of Colorado, Denver, US
- Professor and medical oncologist at the University of Pittsburgh Cancer Institute, US
- Oncologist at University Hospital of Canton Vaud, Lausanne, Switzerland
- Consultant Surgical Oncologist at St Helens Teaching Hospital, St Helens, UK
- Hemato-medical oncologist at Centre Hospitalier de Luxembourg (CHL), Luxembourg
- Professor and Chairman of the Department of Clinical Therapeutics at the University Athens School of Medicine, Athens, Greece
|
|
|
|
